AgeX Therapeutics Inc
AGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.76M
Close$
$-3.97
135.8% downside
Current Fair Value
135.8% downsideOvervalued by 135.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.76 Million |
|---|---|
| Enterprise Value | $3.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 1.19 |
| Outstanding Shares | 12,047,000 |
Return
| Return on Equity | -122.29% |
|---|---|
| Return on Assets | -78.97% |
| Return on Invested Capital | -86.74% |
Valuation & Multiples
| P/E Ratio | -1.04 |
|---|---|
| PEG | -2.36 |
| Price to Sales | - |
| Price to Book Ratio | 11.1 |
| Enterprise Value to Revenue | 26.09 |
| Enterprise Value to EBIT | -0.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AgeX Therapeutics Inc
CEO: Michael West